Allergy development is associated with consumption of breastmilk with a reduced microbial richness in the first month of life
Por:
Dzidic M, Mira A, Artacho A, Abrahamsson TR, Jenmalm MC and Collado MC
Publicada:
1 abr 2020
Ahead of Print:
1 dic 2019
Resumen:
Background Early colonization with a diverse microbiota seems to play a crucial role for appropriate immune maturation during childhood. Breastmilk microbiota is one important source of microbes for the infant, transferred together with maternal IgA antibodies. We previously observed that allergy development during childhood was associated with aberrant IgA responses to the gut microbiota already at 1 month of age, when the IgA antibodies are predominantly maternally derived in breastfed infants. Objective To determine the microbial composition and IgA-coated bacteria in breastmilk in relation to allergy development in children participating in an intervention trial with pre- and post-natal Lactobacillus reuteri supplementation. Methods A combination of flow cytometric cell sorting and 16S rRNA gene sequencing was used to characterize the bacterial recognition patterns by IgA in breastmilk samples collected one month post-partum from 40 mothers whose children did or did not develop allergic and asthmatic symptoms during the first 7 years of age. Results The milk fed to children developing allergic manifestations had significantly lower bacterial richness, when compared to the milk given to children that remained healthy. Probiotic treatment influenced the breastmilk microbiota composition. However, the proportions of IgA-coated bacteria, the total bacterial load and the patterns of IgA-coating were similar in breastmilk between mothers of healthy children and those developing allergies. Conclusion Consumption of breastmilk with a reduced microbial richness in the first month of life may play an important role in allergy development during childhood.
Filiaciones:
:
Institute of Agrochemistry and Food Technology (IATA-CSIC), Department of Biotechnology, Unit of Lactic Acid Bacteria and Probiotics, Valencia, Spain
Department of Health and Genomics, Center for Advanced Research in Public Health, FISABIO, CIBER-ESP, Valencia, Madrid, Spain
Department of Clinical and Experimental Medicine, Division of Autoimmunity and Immune Regulation, Linköping University, Linköping, Sweden
:
Department of Health and Genomics, Center for Advanced Research in Public Health, FISABIO, CIBER-ESP, Valencia, Madrid, Spain
:
Department of Health and Genomics, Center for Advanced Research in Public Health, FISABIO, CIBER-ESP, Valencia, Madrid, Spain
Abrahamsson TR:
Department of Clinical and Experimental Medicine and Department of Pediatrics, Linköping University, Linköping, Sweden
Jenmalm MC:
Department of Clinical and Experimental Medicine, Division of Autoimmunity and Immune Regulation, Linköping University, Linköping, Sweden
Collado MC:
Institute of Agrochemistry and Food Technology (IATA-CSIC), Department of Biotechnology, Unit of Lactic Acid Bacteria and Probiotics, Valencia, Spain
Green Accepted, Green Submitted, Green
|